Anti-Infectives · LP-033
Ciprofloxacin ophthalmic Eye drops
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-033Anti-Infectives
- Generic identity
- Ciprofloxacin ophthalmicEye drops
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-033
- Generic identity
- Ciprofloxacin ophthalmic
- Presentation
- Eye drops
- Catalogue strength
- 0.3%
- Catalogue pack
- Dropper bottle 5 mL
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: ciprofloxacin ophthalmic.
- Dosage form: eye drops.
- Proposed concentration: 0.3%.
- Proposed pack: 5 mL dropper bottle.
Layer 02 · Unresolved product-specific fields
- Final formulation, preservative system, sterility specification and container-closure details.
- Approved ophthalmic indication, administration instructions, warnings and contact-lens guidance.
- Storage, shelf life, after-opening period, registration and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 0.3% | Eye drops | — | 5 mL dropper bottle | Ophthalmic formulation/sterility and authorised instructions require product-specific evidence. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Ciprofloxacin ophthalmic is a fluoroquinolone antibiotic formulated for the eye. Its role is limited to suitable bacterial ocular infections under the applicable product authorization. An eye-drop product is separate from a systemic tablet and should not inherit all systemic indications or handling instructions. This page provides ingredient-and-route education and does not confirm the registered indications, preservative system or sterility-release status of a Luang Pharma presentation.
Clinical context and therapeutic role
An eye examination may be needed to distinguish conjunctivitis from corneal infection, trauma or other causes of a red eye. Pain, reduced vision, light sensitivity or contact-lens-associated symptoms need prompt evaluation. Where bacterial infection is diagnosed, treatment selection considers the site and organism. A general catalogue is not an adequate basis for managing a corneal ulcer or determining whether a particular antibiotic is the best choice.
Selected safety context
Local burning, irritation, temporary blurred vision or an unpleasant taste may occur. Hypersensitivity requires prompt attention. Avoid touching the dropper tip to the eye, fingers or other surfaces, and do not share a bottle. Contact lenses can complicate infection and should be discussed with a professional. Increasing pain, worsening redness, reduced vision or failure to improve requires reassessment. Eye-drop labeling should never be assumed to authorize injection or use at another site.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue identifies an ophthalmic liquid presentation. Ophthalmic suitability, sterility, preservative content, container design and the approved route must be confirmed for the actual product. A percentage strength alone does not establish interchangeability with ear drops, skin solutions or another eye-drop formulation.
Follow hand-hygiene and applicator instructions, avoiding contact between the dropper tip and the eye or other surfaces. Keep the bottle labeled and do not share it. The in-use period, storage conditions and handling after opening are specific to the supplied product.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Sterile finished-product specification and container-closure data.
Approved ophthalmic label/leaflet.
Stability/after-opening evidence.
Registration/market-status and manufacturing-site evidence.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B06 checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: Ciprofloxacin ophthalmicArchived source classification: NLM-hosted medicine monograph | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-033.
Professional enquiries
Request product-specific evidence for LP-033.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.